Elevated MAO-B activity in PD patients exacerbates dopaminergicsystem abnormalities by degrading monoamine neurotransmitters, includingdopamine. Selegiline, a selective MAO-Binhibitor, has demonstrated efficacy as a PD adjunct therapy, highlighting MAO-B’s broader therapeuticpotential in NDDs. Here, MAOB is linked to Parkinson disease.